

Andreas Pahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9578142/publications.pdf>

Version: 2024-02-01

12
papers

458
citations

1163117

8
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

847
citing authors

#	ARTICLE	IF	CITATIONS
1	HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 367-378.	4.1	42
2	Enhancing the Pharmacokinetics and Antitumor Activity of an α -Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc Domain. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4117-4129.	6.4	20
3	Design, Synthesis, and Biochemical Evaluation of α -Amanitin Derivatives Containing Analogs of the <i>trans</i> -Hydroxyproline Residue for Potential Use in Antibody-Drug Conjugates. <i>Chemistry - A European Journal</i> , 2021, 27, 10282-10292.	3.3	7
4	Iodine-Mediated Tryptathionine Formation Facilitates the Synthesis of Amanitins. <i>Journal of the American Chemical Society</i> , 2021, 143, 14322-14331.	13.7	7
5	CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2899-2911.	5.2	36
6	Totalsynthese von α - und β -Amanitin. <i>Angewandte Chemie</i> , 2020, 132, 11486-11490.	2.0	4
7	Total Synthesis of α - and β -Amanitin. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 11390-11393.	13.8	27
8	Amanitins and their development as a payload for antibody-drug conjugates. <i>Drug Discovery Today: Technologies</i> , 2018, 30, 85-89.	4.0	74
9	Synthesis and biological evaluation of RGD and isoDGR peptidomimetic- α -amanitin conjugates for tumor-targeting. <i>Bellstein Journal of Organic Chemistry</i> , 2018, 14, 407-415.	2.2	30
10	HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, e14527-e14527.	1.6	13
11	Abstract 77: Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug conjugate. <i>Cancer Research</i> , 2017, 77, 77-77.	0.9	4
12	TP53 loss creates therapeutic vulnerability in colorectal cancer. <i>Nature</i> , 2015, 520, 697-701.	27.8	192